This website uses cookies to ensure proper functionality of the shopping cart and checkout progress. By continuing to browse the site you are agreeing to the use of cookies. Click here to learn about cookie settings.

Product Description

Details

Diagnostics are leading the charge in reducing the threat posed by antimicrobial resistance. New diagnostic technologies, beyond gene sequencing, are under development to capture this growing market. We have identified the 6 key large pathogen opportunities in this space and developed market forecasts out to 2023. We have looked at the technology picture too, giving you plain language understanding of the different ways pathogens and infections can be diagnosed. We profile 20 companies, large and small, working in this area.

Forecasts are provided to 2023 and are broken out by country, pathogen and five different technology opportunities; Immunoassay, PCR, next-generation sequencing (NGS), mass spectrometry and rapid POC. Additional breakout data relevant to your own areas of interest is available upon request, and free of charge with the report.

All report data is available in Excel format on request.

Make investment decisions and market valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.SC., M.B.A is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell’s education includes:

Reviews

Write Your Own Review

About us

Biopharma Research Ltd is a leading provider of life science market reports and research services. We work with a network of highly reputable publishers to offer you accurate, in-depth market analysis that will save you time, identify key market opportunities, resulting in unquestionable return on investment.